Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 5/20 | 0.66 |
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19228824 | 0.88 | KCNA5 (0.60) | RUNX1DRD3KCNA5DRD2 | |
| SCHEMBL17525977 | 0.86 | RUNX1 (0.68) | RUNX1DRD3KCNA5DRD2 | |
| SCHEMBL17525957 | 0.86 | RUNX1 (0.87) | RUNX1DRD3CBFBKCNA5DRD2 | |
| SCHEMBL17525972 | 0.83 | RUNX1 (0.86) | RUNX1CBFB | |
| SCHEMBL24950551 | 0.77 | CBFB (0.58) | RUNX1CBFB | |
| SCHEMBL30787480 | 0.77 | CBFB (0.58) | RUNX1CBFB | |
| SCHEMBL19970847 | 0.77 | RUNX1 (0.51) | RUNX1DRD3CBFB | |
| SCHEMBL19831268 | 0.76 | CBFB (0.70) | RUNX1CBFB | |
| SCHEMBL19831263 | 0.76 | CBFB (0.70) | RUNX1CBFB | |
| SCHEMBL179114 | 0.76 | CBFB (0.70) | RUNX1CBFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180004-B1 | CANCER THERAPEUTICS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10562890-B2 | Cancer therapeutics | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | RUNX1 1/4885DRD3 4704/4885CBFB 2/4885 |
| US-10562890-B2 | Cancer therapeutics | RUNX1, CBFB, MCL1 | RUNX1 1/4885DRD3 4704/4885CBFB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.